Isolation and characterisation of degradant impurities in dipyridamole formulation.
Dipyridamole is an antithrombotic drug. In the stability study of drug product of Dipyridamole, two unknown impurities (referred as DP-I and DP-II) were detected at levels of 0.25% and 0.54% by gradient reverse phase HPLC method. The drug product was subjected to stress to enhance the level of these impurities. An elegant isocratic preparative method was employed using a Reprosil CN column with a short run time of 14 min to isolate these impurities. The DP-I and DP-II were isolated with purities of 99.1% and 99.8% respectively. Structural studies of these impurities were undertaken using spectroscopic techniques such as IR, NMR and Mass. Based on the spectral data, the structures of DP-I and DP-II have been characterised to be 2,2',2″,2'″-(4-hydroxy-8-(piperidin-1-yl) pyrimido [5,4-d]pyrimidine-2,6 diyl) bis(azanetriyl) tetraethanol, 4-(2-((6-(bis (2-hydroxyethyl) amino)-4, 8-di (piperidin-1-yl) pyrimido [5,4-d] pyrimidin-2-yl) (2-hydroxyethyl) amino) ethoxy)-2, 3-dihydroxy-4-oxobutanoic acid, respectively. A detailed elucidation of the structure is presented in this article.
Analytical Research & Development, Dr. Reddy's Laboratories Ltd., IPD, Bachupally, Hyderabad 500 090, India. venkatasb@drreddys.com
B
B
Venkata Subbaiah
K K
KK
Sree Ganesh
G
G
Vamsi Krishna
K
K
Vyas
R
R
Vasu Dev
K
K
Subramanyam Reddy
D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D002853:Chromatography, Liquid / Q000379:methods; D004176:Dipyridamole / Q000302:isolation & purification* / Q000378:metabolism*; D004340:Drug Contamination; D053719:Tandem Mass Spectrometry / Q000379:methods*
D004176:Dipyridamole